Neoadjuvant Everolimus (RAD001)for Advanced RCC Before Cytoreductive Nephrectomy, With Correlative Tumor Studies (Protocol #: 06-08-20-01)
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2016
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 19 Feb 2016 Status changed from recruiting to discontinued due to difficulty in accrual and by the order of the cancer center, according to ClinicalTrials.gov record.
- 01 Apr 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 01 Apr 2011 Planned end date changed from Jul 2015 to Jul 2016 as reported by ClinicalTrials.gov.